Kornimate/medical-research-clean huggingface dataset:
anesthesia endoscope mask is applied to sedation upper gastrointestinal endoscopic diagnosis and treatment

Conditions: Hypoxemia

Summary: to investigate the efficacy and safety of new-type mask compared with nasal tube oxygen delivery in patients undergoing sedation of upper gastrointestinal endoscopy

this study aims to utilize a large sample, multicenter, prospective clinical trial using a new mask oxygen supply technology. if the study confirms that the new mask can improve the airway safety and effectiveness in patient examinations, while improving examination efficiency and reducing failure rates, it will provide safety assurance for the early diagnosis and treatment of upper gastrointestinal diseases in high-risk populations.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. upcoming upper gastrointestinal sedation procedure; 3. classification under the american association of anesthesiologists (asa) status i-iii; 4. baseline oxygen saturation (spo2) ≥95% in ambient air conditions. exclusion criteria: 1. individuals with previously documented difficulties in mask ventilation (dmv); 2. patients predisposed to aspiration risks or episodes of vomiting; 3. facial or jaw injuries or congenital abnormalities that render conventional face mask application infeasible; 4. an inability or unwillingness to utilize the novel disposable anesthesia face mask.

Keywords: hypoxemia sedation gastrointestinal sedation procedure non-invasive ventilation endoscopy mask
a comparison of esmolol and remifentanil to reduce blood loss

Conditions: Deviation Septum Nasal

Summary: in this prospective randomized study we aimed to compare the effects of esmolol and remifentanil on intraoperative bleeding surgical field conditions in nasal surgery

60 patients with asa i-iiphysical status assigned for septoplasty will be enrolled in this prospective randomized trial. a standardized anesthesia induction and intubation with propofol and rocuronium will be used. patients will be randomized in two groups. group esmolol (group e n=30) will receive esmolol 500 mic kg-1 loading dose and a 50-500 mic kg-1 min-1 infusion and group remifentanil (group r n=30) will receive remifentanil 0.1-0.3 mic kg-1 min-1 infusion to induce controlled hypotension. a 50-60 mmhg mean arterial pressure and a minimum 50 beat min-1 heart rate is targeted. heart rate, blood pressures, peripheral oxygen saturation and bispectral index spectrum (bis) will be recorded. anesthesia maintenance will be provided with o2/n2o and desflurane-propofol balanced anesthesia and a bis value 40-60 is targeted. the quality of the surgical field will be assessed by the surgeon by using a 10 point visual analog scale (b1) and a 6 point scale (b2) during surgery with 5 minute intervals. the amount of bleeding will be calculated at the end of surgery from the amount of blood and irrigation fluid collected in the suction tube. all complications and side effects will be recorded.

Eligibility criteria:
inclusion criteria: * asa i-ii, * between age 20-60 exclusion criteria: * patients having bleeding disorders, * arrhythmia, * hypertension, * endocrine, liver or kidney disease and * those who are on antihypertensive, * anticoagulant drugs
radiation therapy or no further treatment following surgery in treating patients with cancer of the uterus

Conditions: Endometrial Cancer; Sarcoma

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. it is not yet known whether receiving radiation therapy or no further therapy after surgery is more effective for cancer of the uterus. purpose: randomized phase iii trial to compare the effectiveness of radiation therapy with that of no further therapy in treating patients who have stage i or stage ii cancer of the uterus that has been surgically removed.

objectives: i. compare the rates of pelvic recurrence and development of distant metastases in patients with completely resected, stage i or ii, high-grade uterine sarcoma treated with adjuvant pelvic radiotherapy vs observation alone. outline: this is a randomized, multicenter study. patients are stratified according to center, tumor histology (leiomyosarcoma vs mixed mesodermal sarcoma vs endometrial stromal sarcoma), and surgical procedure (total abdominal hysterectomy (tah) with or without bilateral salpingo-oophorectomy (bso) vs tah and bso with pelvic and para-aortic node sampling and random biopsies). patients are randomized to 1 of 2 treatment arms. arm i: beginning within 6 weeks after surgery, patients undergo pelvic radiotherapy 5 days a week for 5.6 weeks. arm ii: patients undergo observation alone. patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months thereafter. projected accrual: a total of 200 patients (100 per arm) will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: histologically proven high-grade uterine sarcoma eligible subtypes: leiomyosarcoma mixed mesodermal (mullerian) sarcoma endometrial sarcoma surgically proven stage i or ii (t1-2, n0, m0) disease no leiomyoma with a high mitotic activity index after hormonal therapy (especially estrogen) mixoid leiomyosarcoma with a low mitotic activity index allowed completely resected disease prior abdominal hysterectomy as minimal surgical procedure required patient characteristics: age: any age performance status: who 0-2 life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix no serious mental disorder prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: see disease characteristics radiotherapy: no prior radiotherapy surgery: see disease characteristics

Keywords: stage i uterine sarcoma stage ii uterine sarcoma uterine carcinosarcoma uterine leiomyosarcoma endometrial stromal sarcoma
role of serum albumin and total protein in survival of cancer cachectic patients

Conditions: Cancer

Summary: serum albumin can indicate the onset of cancer cachexia, provide information about a patient's nutritional status, and serve as a biomarker for the prognosis of patients with cancer cachexia. however, the relationship between serum albumin levels and mortality in patients with cancer cachexia remains unclear. we aimed to examine the association of albumin and total protein with 1-year mortality in patients with cancer cachexia

cancer cachexia is defined as a multifactorial and multi-organ syndrome characterized by the loss of skeletal muscle mass (with or without loss of adipose tissue), which cannot be fully reversed by conventional nutritional support. in recent years, cancer cachexia has increasingly been seen as a systemic phenomenon that affects various organs, such as the liver and myocardial tissue. cachexia is closely related to anorexia, inflammation, insulin resistance, and decreased protein levels, which can lead to progressive functional impairment, treatment-related complications, poor quality of life, and cancer-related death. its pathophysiology is characterized by a negative protein and energy balance. however, there are no clear clinical guidelines to effectively combat the progressive tissue loss associated with cachexia. cancer cachexia occurs mostly in advanced cancers, with more than half of patients with cancer having cachexia in the later stages, and \>10% of patients die with or from it. studies have shown that cachexia can be diagnosed when weight loss in the past 12 months is ≥5%, and the physiological variables of patients match at least threeof the following five criteria: decreased muscle strength,fatigue, anorexia, low fat-free mass index (ffmi), and abnormal blood profile. albumin and total protein are two variables that reflect an individual's nutritional status and disease severity. additionally, albumin can serve as an indicator of the inflammatory response and is considered a highly sensitive marker of a patient's nutritional status. serum albumin and total protein can be used to define cancer cachexia and cancer-related malnutrition; patients with cachexia have lower total protein and albumin levels than those without cachexia.5 serum albumin may serve as a prognostic factor for treatment outcomes and compliance in patients with advanced cancer. although a reduction in albumin and total protein levels are associated with the diagnosis of cancer related cachexia, no studies have shown that albumin and total protein can predict mortality in patients with cancer cachexia. here, we describe a prospective non randomized study that will be conducted to explore the association between serum albumin and total protein levels and 1-year mortality in patients with cancer cachexia .

Eligibility criteria:
inclusion criteria: * patients who will accept to participate in our study with diagnosis of cancer cachexia exclusion criteria: * patients who not fulfill criteria of cance cachexia
study of arsha vidya chhatralaya initiative on health and functioning of disadvantaged tribal children

Conditions: Physical Disorder; Mental Health Wellness; Social Function Disorder, Childhood or Adolescent; Malnutrition

Summary: india's poor tribal communities have far worse health and social indicators than the general population. most tribal people live in remote forested or desert areas where illiteracy, trying physical environments, malnutrition, inadequate access to potable water, and lack of personal hygiene and sanitation make them more vulnerable to disease.the aim of chhatralaya initiatives taken by arsha vidya, jaipur was to address the exclusion of the socially and economically disadvantaged children of the tribes and to provide a fair opportunity to all.


Eligibility criteria:
inclusion criteria: * children selected from udaipur tribal areas as lacking parental care and basic services; * children living in udaipur tribal areas; * children from 8 years to 16 years of age exclusion criteria:
topical insulin versus autologous serum after corneal surgeries

Conditions: Corneal Epithelial Wound

Summary: the aim of the study is to test whether use of topical insulin or autologous serum eye-drops can promote corneal epithelial healing following photorefractive keratectomy (prk).

topical insulin has been proved recently to enhance the corneal reepithelization rate and manage neurotrophic corneal ulcers unresponsive to conventional treatments. however, its effectiveness on corneal epithelial wound healing in patients who received photorefractive keratectomy (prk) has not been reported. in this study, we plan to perform a prospective non-randomized study to determine the efficacy and safety of topical insulin as a primary treatment for a corneal epithelial defect in patients undergoing the prk and compare that to autologous serum eye drops. the study eye will receive either the insulin or the serum eye drops, in addition to the conventional treatment, while the control eye will have the standard treatment. for each eligible candidate, the eye with a higher depth of ablation will be the study eye. if even ablation depth in both eyes, the right eye will be selected. the conventional postoperative eye drops include topical moxifloxacin 0.5% (vigamox; alcon laboratories) four times per day, artificial tears (systane ultra; alcon) every two hours, dexamethasone 0.1% (maxidex; alcon laboratories) four times daily for one month followed by fluorometholone 0.1% (efemyo; orchidialaboratories) four times daily for another two to four weeks depending on refraction and haze level. in study eyes, the patients receive either topical insulin eye drops or autologous serum in addition to conventional postoperative eye drops until complete epithelial healing. the duration for the corneal surface to completely re-epithelize, the grade of postoperative corneal haze, the incidence of corneal complications due to delayed surface re-epithelization (e.g. infectious corneal ulcer, corneal melting, sterile corneal ulcer, corneal neovascularization), and the distant corrected visual acuity will be compared between these three groups.

Eligibility criteria:
inclusion criteria: * stable refraction of at least one year, normal corneal topography, and a minimum central corneal thickness of 500 μm. exclusion criteria: * unstable refraction, dry eye, blepharitis, corneal disease, glaucoma, systemic diseases including infectious and collagen vascular diseases, diabetes, and topographical evidence of keratoconus.

Keywords: lasik prk topical insulin autologous serum
a study of vgl101 in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Conditions: ALSP

Summary: this is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as vgl101) in subjects with documentation of a gene mutation in the csf1r gene for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (alsp) and to evaluate the effects of iluzanebart on imaging and biomarkers of disease progression in subjects with alsp. participants will receive infusions of iluzanebart approximately every 4 weeks for 1 year. the study includes a 52-week, open-label core study, followed by a long-term extension (lte), which provides subjects who complete the original 52-week study (core study) with the option to continue treatment for up to an additional 2 years.


Eligibility criteria:
key inclusion criteria: * participants who have documentation of a gene mutation in the csf1r gene * participants fulfill both (parts a and b) of the following criteria: 1. the participant has more than 2 findings of clinical signs or symptoms in the following categories: 1. cognitive impairment or psychiatric problem 2. pyramidal signs on neurological examination 3. extrapyramidal signs, such as rigidity. 4. epilepsy 2. mri findings consistent with alsp, specifically, bilateral cerebral white matter lesions with or without thinning of the corpus callosum, on the screening mri. * the participant must have a study partner (i.e., caregiver, family member, friend, etc.) who, in the investigator's judgment, has frequent and sufficient contact with the subject so as to be able to provide accurate information about the participant's health and cognitive and functional abilities. the study partner must be willing to sign a study partner icf. key exclusion criteria: * the participant has any neurological disease that poses a risk to the participant or can produce cognitive, motor, or behavioral impairment similar to alsp, including, but not limited to, brain tumor, hydrocephalus, alzheimer's disease, frontotemporal dementia (ftd), als, stroke, huntington disease, multiple sclerosis, parkinson's disease, and down syndrome. * participant with any condition or situation that, in the opinion of the investigator or sponsor medical personnel, may place the subject at significant risk, confound the study results, or interfere significantly with the participant's participation in the study.

Keywords: alsp csf1r leukoencephalopathy hereditary diffuse leukoencephalopathy with spheroids hdls csf1r-related leukoencephalopathy adult-onset leukoencephalopathy with axonal spheroids and pigmented glia csf1r gene mutation ignite
shared decision making with pharmaceutical care

Conditions: Diabetes

Summary: a research study to enhance clinical discussion between patients and pharmacists using a shared decision making tool for type 2 diabetes or usual care.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age * diagnosed with type ii diabetes by icd-9 code for more than one year * hba1c of 7%-9.5% within past 6 months * prescribed three or less anti-hyperglycemic medications as indicated by the medication list within the medical record exclusion criteria: * prescribed insulin * pregnancy * appointment with provider within a month * appointment with provider within the last month * followed by endocrinology
clinical trial of tqb2928 in combination with a third-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki) in patients with advanced non-small cell lung cancers

Conditions: Advanced Non-small Cell Lung Cancer

Summary: this is a phase ib study to evaluate the safety, tolerability, and efficacy of tqb2928 in combination with third-generation egfr tkis in subjects with advanced non-small cell lung cancer, and to determine the recommended phase ii dose (rp2cd).


Eligibility criteria:
inclusion criteria: * age: 18-75 years; eastern cooperative oncology group (ecog) score: 0-1; expected survival of more than 3 months； * locally advanced or metastatic nsclc diagnosed by histology or cytology * the major organs are functioning well； * negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception for the duration of the study and for 6 months after the end of the study； * subjects voluntarily joined this study, signed the informed consent form, and had good compliance. exclusion criteria: * current concomitant presence of other malignancies within 5 years prior to the first dose; * unresolved toxicity above ctcae grade 1 due to any prior anti-tumor therapy; * significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose; * long-term unhealed wounds or fractures; * cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose; * a history of psychotropic drug abuse and cannot be abstained from or have a mental disorder; * subjects with any severe and/or uncontrolled disease; * history of live attenuated vaccination within 2 weeks prior to the first dose or planned live attenuated vaccination during the study; * previous history of unexplained severe allergies, hypersensitivity to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to tqb2928 injection or excipients in pharmaceutical formulations; * according to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patients or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.
nifedipine treatment in preterm labor

Conditions: Threatened Preterm Labor

Summary: this is a study for pregnant women who have been diagnosed with threatened preterm labor. the principal aim of this study is to compare the efficacy and safety of nifedipine treatment versus atosiban treatment over these patients' newborn babies.

preterm labor is defined as the presence of uterine contractions of sufficient frequency and intensity to effect progressive effacement and dilation of the cervix prior to term gestation (between 20 and 37 weeks). it is a major health problem of increased incidence, affecting approximately between 7-10% of pregnant women in developed countries with a high socioeconomic costs and high rates of fetal mortality, although perinatal progress. this study may allow to establish the existence of differences in perinatal outcomes and to define the first choice drug for tocolysis.

Eligibility criteria:
inclusion criteria: the study population and the inclusion criteria is established by patients between the 24th and 33+6th weeks of pregnancy, fixed by an ecography during the first three-month period, and with a threat of preterm labor (tlp), by the american college of obstetricians and gynecologists (acog's) criteria: * four contractions or more with a duration of at least 30 seconds during 30 minutes * documented cervix changes: * the cervix changes in a nulliparous woman are: both cervix tact with 0 to 4 cm of dilatation and cervical effacement of at least a 50% (vaginal ultrasound alternative with cervix length two standard curvatures under the average for the gestational age) * the cervix changes in a multiparous woman are: 1 to 4 cm of dilatation and cervical effacement of at least a 50% (same ecographic alternative as the nulliparous). * patient who had signed the informed consent. exclusion criteria: exclusion criteria of the pregnant mother and intrauterine fetal: * prior treatment with a different tocolytic from the ones in the protocol. * chorioamnionitis. * premature rupture of membranes. * vaginal bleeding. * major fetal malformations. * intrauterine growth retardation (igr): igr\<percentile 5. * cardiopathies (aortic stenosis, congestive heart failure). * blood pressure lower than 100/60 mmhg. * high transaminase levels. * uterine malformations. * use of magnesium sulphate. * severe hypertensive disorder, defined as blood pressure equal to or greater than 160/100 mmhg or any figure associated with severe preeclampsia. * non-reassuring cardiac frequency tracing defined as category ii and iii of national institute of child health and human development (nichd). * asthmatic patients treated with betamimetics. * hypertensive patients treated with vasodilators. * patient in treatment or treated with another product/s in investigation during the four weeks prior to randomization. * hypersensitivity to any drug of the study.

Keywords: nifedipine obstetric labor premature tocolysis
effects of a low carb diet on erectile function and serem testosterone in men with metabolic syndrome

Conditions: Testosterone Deficiency; Metabolic Syndrome; Diet Modification

Summary: investigate if low carb diet could increase serum testosterone level in hypogonadic men

randomized controlled trial to evaluate the effect of low carb diet in men with metabolic syndrome and low testosterone level. the inclusion criteria is men with metabolic syndrome and serum total testosterone below 300 ng/dl. they will randomized to perform a low carb diet or a traditional low fat diet for metabolic syndrome. the follow up will be of three months with a once a month visit. even though these men will be looked at their sexuality and life style. they will be monitoring by urologists and nutritionists during the study.

Eligibility criteria:
inclusion criteria: * metabolic syndrome, serum testosterone level below 300 ng/dl exclusion criteria: * active cancer, diet allergies, psychological incapability

Keywords: low carb diet hypogonadism metabolic syndrome
the journey of children with cow's milk protein allergy in mexico.

Conditions: Cow's Milk Protein Allergy

Summary: to gain insights on the application, use and effectiveness of frisolac gold intensive ha and frisolac gold pep ac with reference to improvement of cmpa symptoms and to determine the methodology used by mexican health care professionals (hcps) in the clinical practice (i.e. diagnosis and dietary management) of cmpa in mexican children (≤24 months) diagnosed with or suspected of cmpa.


Eligibility criteria:
inclusion criteria: * subjects with electronic/physical medical records that contain sufficient data to answer the primary question (i.e. data on growth and dermatological symptoms (based on the scorad score) at diagnosis and follow up data of at least 2 months or successful completion of therapy according to the pi (whichever comes first). * subjects ≤24 months of age at the moment of suspected or diagnosed cmpa with records available between january 2016 to september 2020. * subjects prescribed with frisolac gold intensive ha and/or frisolac gold pep ac for the dietary management of their cmpa symptoms. exclusion criteria: * subjects using other formula products/breast milk alongside frisolac gold intensive ha or frisolac gold pep ac during the time of their participation in the study. * premature children, or children with low birth-weight (weight at birth \<2.5 kg). * subjects diagnosed with a metabolic condition that impacts development and growth. * subjects diagnosed with a congenital condition and/or with prior or current disease that in the opinion of the pi could potentially interfere with their participation in the study.